NeuroRx to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019

Wilmington, DE / Radnor, PA – September **6**, 2019 – NeuroRx, a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, today announced that Jonathan Javitt, M.D., M.P.H., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference in New York. In addition to the presentation, Dr. Javitt will be available for 1x1 meetings.

H.C. Wainwright 21st Annual Global Investment Conference

Date: September 9, 2019

Time: 3:00pm Eastern Time

Location: Lotte New York Palace Hotel, New York

About Bipolar Depression and Acute Suicidal Ideation and Behavior (ASIB)

Bipolar disorder, which affects 5.7 million Americans, is characterized by significant changes in mood, from mania or hypomania to depression, often quite severe. The depressive phase can trigger suicidal thoughts and behaviors. Currently the only FDA-approved treatment for suicidal bipolar depression is electroconvulsive therapy (ECT), which is shown to increase levels of glutamate/glutamine (Glx) in the brain. Despite its effectiveness, ECT has a myriad of well-known adverse side effects, including confusion and memory loss. Unfortunately, most commonly-used antidepressants have an FDA mandated warning label identifying the potential to increase the risk of suicide.

Each day, approximately 120 Americans, and more than 2,100 people worldwide, end their lives by suicide, according to the American Foundation for Suicide Prevention (AFSP) and the World Health Organization (WHO). Individuals who suffer from bipolar depression are at far greater risk of suicide than those with major depressive disorder and are believed to represent between 25% and 40% of the 45,000 who end their lives each year in the United States. 11%-20% of those diagnosed with bipolar disorder are believed to take their lives at some point. Overall, suicide has become a national epidemic and is the 10th leading cause of death in the United States.

About NRX-101

NRX-101 is a patented, oral, fixed-dose combination of two FDA approved drugs: D-cycloserine, a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, which has D2/5-HT2a receptor antagonist activity. D-cycloserine has shown activity against depression in four clinical studies. It has also shown an effect on suicidality in some of these studies. NRX-101 is designed to address bipolar depression with suicidal ideation, an indication for which there currently is no approved drug and for which the only FDA-approved treatment remains electroconvulsive therapy (ECT). NeuroRx was granted Fast Track designation by the U.S. FDA for this indication in August 2017. In May of 2018 NeuroRx was awarded a Special Protocol Agreement (SPA) by the FDA for the NRX-101 phase 2b/3 trial. In April 2018,

NeuroRx received a biomarker letter of support from the FDA, documenting that the company had shared evidence of increased Glx levels associated with oral administration of D-cycloserine, a phenomenon not seen with serotonin-targeted drugs (SSRI). In November 2018, the FDA awarded NeuroRx Breakthrough Therapy designation for NRX-101.

About NeuroRx, Inc.

NeuroRx draws upon 30 years of basic science and clinical expertise in the role of N-methyl-Daspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality, as well as PTSD. The company is privately funded and led by former senior executives of Johnson & Johnson, Pfizer Inc., Eli Lilly, and Astra-Zeneca. NeuroRx's Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary for Planning and Evaluation, Department of the U.S. Health and Human Services; Chaim Hurvitz, former President, TEVA International Group; Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

Learn more at www.Neurorxpharma.com

For further information, please contact:

Investor Contact:

Brian Korb
Solebury Trout
+1-646-378-2923
bkorb@soleburytrout.com